EP3271399A4 - Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques - Google Patents

Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques Download PDF

Info

Publication number
EP3271399A4
EP3271399A4 EP16765875.6A EP16765875A EP3271399A4 EP 3271399 A4 EP3271399 A4 EP 3271399A4 EP 16765875 A EP16765875 A EP 16765875A EP 3271399 A4 EP3271399 A4 EP 3271399A4
Authority
EP
European Patent Office
Prior art keywords
haematopoietic
targeting
compositions
methods
lymphoid malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16765875.6A
Other languages
German (de)
English (en)
Other versions
EP3271399A2 (fr
Inventor
Christopher Y. PARK
Stephen Shiu-Sah CHUNG
Montreh TAVAKKOLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP3271399A2 publication Critical patent/EP3271399A2/fr
Publication of EP3271399A4 publication Critical patent/EP3271399A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP16765875.6A 2015-03-18 2016-03-18 Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques Withdrawn EP3271399A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135119P 2015-03-18 2015-03-18
PCT/US2016/023303 WO2016149682A2 (fr) 2015-03-18 2016-03-18 Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques

Publications (2)

Publication Number Publication Date
EP3271399A2 EP3271399A2 (fr) 2018-01-24
EP3271399A4 true EP3271399A4 (fr) 2019-03-20

Family

ID=56919925

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16765875.6A Withdrawn EP3271399A4 (fr) 2015-03-18 2016-03-18 Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques

Country Status (9)

Country Link
EP (1) EP3271399A4 (fr)
JP (1) JP2018511311A (fr)
KR (1) KR20170136535A (fr)
CN (1) CN107614531A (fr)
AU (1) AU2016232719A1 (fr)
BR (1) BR112017019856A2 (fr)
CA (1) CA2980038A1 (fr)
MX (1) MX2017011882A (fr)
WO (1) WO2016149682A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7281824B2 (ja) * 2018-01-08 2023-05-26 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｃｄ９９－発現癌を標的にするための組成物および方法
EP3801771A1 (fr) * 2018-06-04 2021-04-14 Diatheva S.r.l. Dianticorps anti-cd99 ou anticorps igg et utilisations correspondantes
IT201800005991A1 (it) * 2018-06-04 2019-12-04 Complesso anticorpale ed usi derivati

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069935A1 (fr) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions et méthodes de traitement des leucémies aiguës myéloblastiques et des syndromes myélodysplasiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
WO2006024169A1 (fr) * 2004-09-01 2006-03-09 Hemax Genome Inc. Genes de la region pseudoautosomale 1 et leur utilisation dans le diagnostic, le traitement et la prevention de maladies auto-immunes
CN101437539B (zh) * 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
US20110230372A1 (en) * 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
ES2927646T3 (es) * 2009-09-15 2022-11-08 Univ Leland Stanford Junior Terapia anti-CD47 sinérgica para cánceres hematológicos
CA2863658C (fr) * 2012-02-03 2023-03-14 Emory University Compositions immunostimulatrices, particules et applications associees
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069935A1 (fr) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions et méthodes de traitement des leucémies aiguës myéloblastiques et des syndromes myélodysplasiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUNG ET AL: "CD99 IS A DIAGNOSTIC AND THERAPEUTIC TARGET ON DISEASE STEM C ells in MDS and AML", MOLECULAR CLASSIFICATION OF MELANOMAS AND NEVI USING GENE EXPRESSION MICROARRAY SIGNATURES AND FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE,, vol. 27, no. 2, 1 January 2014 (2014-01-01), pages 343A, XP009506706, ISSN: 1530-0285 *
JUNG K C ET AL: "The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat", FEBS LETT, ELSEVIER, AMSTERDAM, NL, vol. 554, no. 3, 20 November 2003 (2003-11-20), pages 478 - 484, XP004472972, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(03)01224-9 *
STEPHEN S CHUNG ET AL: "3760: CD99 IS A THERAPEUTIC TARGET ON DISEASE INITIATING STEM CELLS IN ACUTE MYELOID LEUKEMIA AND THE MYELODYSPLASTIC SYNDROMES", vol. 124, no. 21, 6 December 2014 (2014-12-06), pages 3760, XP009506732, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/124/21/3760> *
STEPHEN S CHUNG ET AL: "CD99 IS A THERAPEUTIC TARGET ON DISEASE STEM CELLS IN ACUTE M yeloid Leukemia and The Myelodysplastic Syndromes", vol. 122, no. 21, 15 November 2013 (2013-11-15), pages 2891, XP009506733, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/122/21/2891> *

Also Published As

Publication number Publication date
CA2980038A1 (fr) 2016-09-22
EP3271399A2 (fr) 2018-01-24
WO2016149682A2 (fr) 2016-09-22
JP2018511311A (ja) 2018-04-26
WO2016149682A3 (fr) 2017-01-26
BR112017019856A2 (pt) 2018-05-29
CN107614531A (zh) 2018-01-19
MX2017011882A (es) 2018-04-20
AU2016232719A1 (en) 2017-10-12
KR20170136535A (ko) 2017-12-11

Similar Documents

Publication Publication Date Title
HK1258900A1 (zh) 遞送方法和組合物
SG11202001208XA (en) Rna targeting methods and compositions
HK1253674A1 (zh) 用於具有增强的穩定性的瞬時基因療法的組合物和方法
EP3097212A4 (fr) Méthodes et compositions pour des séquences guidant le ciblage de cas9
IL254811A0 (en) Hahaha
EP3362103A4 (fr) Compositions et procédés faisant appel à des néo-épitopes cancéreux viraux
EP3151846A4 (fr) Méthodes et compositions de conception de nucléase
EP3166640A4 (fr) Compositions de thérapie combinatoire et méthodes de traitement de cancers
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3152222A4 (fr) Compositions et procédés pour cibler une voie
EP3233192A4 (fr) Compositions et méthodes pour l&#39;administration ciblée de médicaments
EP3331612A4 (fr) Procédés et compositions destinés à la thérapie de tumeurs
EP3220906A4 (fr) Compositions et procédés de traitement de troubles lysosomaux
IL258292A (en) Methods and compositions for reducing metastases
EP3200815A4 (fr) Procédés et compositions pour le traitement du cancer
EP3209298A4 (fr) Compositions et méthodes pour traiter l&#39;insomnie
EP3137571A4 (fr) Compositions servant à la protection contre la corrosion
ZA201803723B (en) Compositions and methods for efficient targeting of transgenes
EP3091999A4 (fr) Compositions cellulaires améliorées et procédés pour la thérapie du cancer
EP3116489A4 (fr) Procédés et compositions pour administration transdermique
EP3110422A4 (fr) Compositions et méthodes d&#39;administration d&#39;agents thérapeutiques
EP3154544A4 (fr) Compositions et procédés de traitement de cancers
EP3223793A4 (fr) Compositions et procédés d&#39;administration d&#39;un agent bio-actif ou d&#39;agents bio-actifs
EP3169333A4 (fr) Méthodes et compositions pour améliorer un traitement anticancéreux
EP3203995A4 (fr) Compositions et méthodes d&#39;administration d&#39;agents thérapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171009

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190214

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20190208BHEP

Ipc: G01N 33/574 20060101ALI20190208BHEP

Ipc: C12Q 1/68 20180101ALI20190208BHEP

Ipc: C07K 16/28 20060101ALI20190208BHEP

Ipc: A61P 35/02 20060101ALI20190208BHEP

Ipc: C07K 16/30 20060101AFI20190208BHEP

Ipc: C12Q 1/6886 20180101ALI20190208BHEP

Ipc: A61K 39/00 20060101ALI20190208BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190917